Crossmark

Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors

Crossref DOI link: https://doi.org/10.1186/s12885-026-15733-9

Published Online: 2026-02-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Matsuura, Shun

Kita, Kensuke

Matsushita, Kyohei

Nagasaki, Takumi

Suzuki, Ryo

Yamamoto, Yuya

Yamada, Kotaro

Nakamura, Ryuuichi

Akiyama, Norimichi

Tanaka, Kazuki

Koshimizu, Naoki
License Information

Text and Data Mining valid from 2026-02-12

Version of Record valid from 2026-03-24
More Information

Article History

Received: 20 November 2025

Accepted: 10 February 2026

First Online: 12 February 2026

Declarations

:

: The requirement for written informed consent was waived by the medical ethics committee of the Fujieda Municipal General Hospital (R07-29), owing to the retrospective design of the study and the use of de-identified patient data, which posed no risk to individuals.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below